Shares of Delcath Systems (DCTH) +30% premarket after the FDA granted its liver cancer...

|About: Delcath Systems, Inc. (DCTH)|By:, SA News Editor

Shares of Delcath Systems (DCTH) +30% premarket after the FDA granted its liver cancer treatment, doxorubicin, orphan drug status, which would give it seven years of market exclusivity.